Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > TSX Interview

<< Previous

Bullboard Posts

Next >>

Comment by crow27on Nov 26, 2020 1:55pm

200 Views

Post# 31982180

RE:RE:RE:RE:TSX Interview

We need some players to come in and buy a few million shares here and there. That will just slop up the cheap shares that are being traded back and forth. This can happen at any time, could be today/could be in 2 months. Once the RS is complete then the float is much lower and 5 to 10 million shares traded will make this stock fly.
But for now we just keep letting the news flow. One of these NR's will finally break ATE out of this trading range.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China